Clinical trials: Resected Pancreatic Adenocarcinoma
Pancreatic Cancer
GVAX Pancreas Vaccine (With CY) in Combination With Nivolumab and SBRT for Patients With Borderline Resectable Pancreatic Cancer
The purpose of this study is to evaluate the safety and clinical activity of FOLFIRINOX along with a whole cell vaccine with immune modulating doses of cyclophosphamide and nivolumab combined with Stereotactic Body Radiation…
- Trial name
- NCT03161379
- Testing
- Cyclophosphamide, Nivolumab, GVAX Pancreas Vaccine
- Where
- 2 sites in United States
- Volunteers
- 31 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Pancreatic Cancer
Two Stage Study Of Single Dose PEGPH20 And Cetuximab In Patients With Pancreatic Adenocarcinoma Prior To Surgical Resection
This study has several purposes. DCE-MRI will be used to image the tumor. Safety of cetuximab given before surgery will be studied. Cetuximab delivery to the tumor will be studied.
- Trial name
- NCT02241187
- Testing
- PEGPH20, Cetuximab, DW & DCE-MRI
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Cholangiocarcinoma Cancer, Gallbladder Cancer
A Feasibility Phase II Study in the Treatment of Resected Cholangiocarcinoma, Gallbladder, Pancreatic and Ampullary Cancers
To assess the feasibility of administering induction chemotherapy with gemcitabine and docetaxel followed by concurrent radiation and continuous infusion 5FU and consolidation gemcitabine/docetaxel chemotherapy.
- Conditions
- Cholangiocarcinoma Cancer, Gallbladder Cancer, Pancreatic Cancer, Ampullary Cancer
- Trial name
- NCT00660699
- Testing
- Gemcitabine, Docetaxel, Radiation
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Washington University School of Medicine
Colon Cancer, Pancreatic Cancer
Perioperative MVT-5873, a Fully Human Monoclonal Antibody Against a CA 19-9 Epitope, for Operable CA 19-9 Producing Pancreatic Cancers, Cholangiocarcinomas, and Metastatic Colorectal Cancers
Background: Gastrointestinal tumors have a molecule called carbohydrate antigen 19-9 (CA19-9) in the tumors and blood. The agent MVT-5873 was designed to block this molecule.
- Conditions
- Colon Cancer, Pancreatic Cancer, Cholangiocarcinoma, Metastatic Colon Carcinoma
- Trial name
- NCT03801915
- Testing
- MVT-5873, pancreatectomy or hepatectomy
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- National Cancer Institute (NCI)
Resected Pancreatic Adenocarcinoma
Study of Proton Therapy in Adjuvant Pancreatic Cancer
This trial aims to determine a safe schedule of short-course proton beam radiation therapy with adjuvant mFOLFIRINOX for patients with resected pancreatic adenocarcinoma.
- Trial name
- Proton-PANC (NCT03885284)
- Testing
- mFOLFIRINOX, Proton beam radiation
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Georgetown University
Pancreatic Adenocarcinoma, Pancreatic Ductal Adenocarcinoma
Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed by the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed by Surgery
This randomized phase II-R/III trial studies gemcitabine hydrochloride with or without erlotinib hydrochloride followed by the same chemotherapy regimen with or without radiation therapy and capecitabine or fluorouracil in…
- Conditions
- Pancreatic Adenocarcinoma, Pancreatic Ductal Adenocarcinoma, Pancreatic Intraductal Papillary-Mucinous Neoplasm, Stage I Pancreatic Cancer AJCC v6 and v7
- Trial name
- NCT01013649
- Testing
- 3-Dimensional Conformal Radiation Therapy, Biospecimen Collection, Capecitabine
- Where
- 689 sites in United States, Belgium and 2 more
- Volunteers
- 546 people
- Sponsor
- National Cancer Institute (NCI)
Pancreatic Adenocarcinoma
Study of CAP1-6D in Patients With Locally Advanced or Surgically Resected Pancreatic Adenocarcinoma
The purpose of this study is to determine whether the experimental vaccine "modified CEA peptide CAP 1 -6D" (mCEA) can produce an immune response in patients with pancreatic cancer who have received chemotherapy and radiation…
- Trial name
- NCT00203892
- Testing
- modified CEA peptide (10mcg), modified CEA peptide (100mcg), modified CEA peptide (1000mcg)
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- University of Chicago
Pancreatic Cancer, Resected
Antigen-specific Cancer Immunotherapy (TG01) and Gemcitabine as Adjuvant Therapy in Resected Pancreatic Cancer
The purpose of this study is to investigate the effect of TG01 and Granulocyte macrophage colony stimulating factor (GM-CSF) when given in addition to gemcitabine (chemotherapy) and Understand any possible side effects of the…
- Trial name
- NCT02261714
- Testing
- TG01
- Where
- 5 sites in Norway, Spain and 1 more
- Volunteers
- 32 people
- Sponsor
- Targovax ASA
Pancreatic Cancer
Chemotherapy, Interferon Alfa, and Radiation Therapy in Treating Patients Who Have Undergone Surgery For Pancreatic Cancer
RATIONALE: Drugs used in chemotherapy, such as cisplatin and fluorouracil, use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00068575
- Testing
- Recombinant Interferon Alfa, Cisplatin, Fluorouracil
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- M.D. Anderson Cancer Center
Pancreatic Cancer
Vaccine Therapy Combined With Adjuvant Chemoradiotherapy in Treating Patients With Resected Stage I or Stage II Adenocarcinoma (Cancer) of the Pancreas
RATIONALE: Vaccines made from gene-modified pancreatic cancer cells may make the body build an immune response to kill tumor cells.
- Trial name
- NCT00084383
- Testing
- GVAX pancreatic cancer vaccine
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Pancreatic Cancer
Pancreatic Tumor Cell Vaccine (GVAX), Cyclophosphamide, SBRT, and FOLFIRINOX in Patients With Resected Adenocarcinoma of the Pancreas
The purpose of this study is to estimate safety of GVAX Pancreas Vaccine (GVAX) with immune modulating doses of cyclophosphamide (Cy) followed by SBRT and FOLFIRINOX chemotherapy in pancreatic cancer patients after surgery.
- Trial name
- NCT01595321
- Testing
- Cyclophosphamide, GVAX Pancreas Vaccine, Stereotactic Body Radiation
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Adenocarcinoma of Pancreas
FOLFIRINOX in Patients With Inoperable Pancreatic Cancer
The prognosis of patients with locally advanced unresectable pancreatic cancer is poor, and the median survival is less than 1 year.
- Trial name
- NCT01359007
- Testing
- Irinotecan, Oxaliplatin, Leucovorin, 5-FU
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- University of Oklahoma
Adenocarcinoma of the Pancreas, Stage IA Pancreatic Cancer
Perioperative Therapy for Resectable Pancreatic Cancer
This phase II trial studies how well giving combination chemotherapy together with intensity-modulated radiation therapy (IMRT) and surgery works in treating patients with localized pancreatic cancer that can be removed by…
- Conditions
- Adenocarcinoma of the Pancreas, Stage IA Pancreatic Cancer, Stage IB Pancreatic Cancer, Stage IIA Pancreatic Cancer
- Trial name
- NCT00609336
- Testing
- gemcitabine hydrochloride, docetaxel, capecitabine
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- University of Washington
Adenocarcinoma of the Pancreas
SBRT for Close or Positive Margins After Resection of Pancreatic Adenocarcinoma
The current study seeks to further investigate the impact of Stereotactic Body Radiation Therapy following pancreatic resection with a close or positive margin.
- Trial name
- NCT01357525
- Testing
- Stereotactic Body Radiation Therapy (SBRT)
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- David A. Clump, MD, PhD
Pancreatic Cancer
Boost GVAX Pancreas Vaccine With or Without CY in Patients With Pancreas Cancer
The purpose of this study is to evaluate the safety and feasibility of long term boost vaccination of a lethally irradiated, allogenic pancreatic tumor cell vaccine transfected with the granulocyte macrophage colony-stimulating…
- Trial name
- NCT01088789
- Testing
- Cyclophosphamide, Cyclophosphamide Pill, GVAX Pancreas Vaccine
- Where
- United States
- Volunteers
- 71 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Pancreatic Cancer
Vaccine Therapy With or Without Cyclophosphamide in Treating Patients Undergoing Chemotherapy and Radiation Therapy for Stage I or Stage II Pancreatic Cancer That Can Be Removed by Surgery
RATIONALE: Vaccines made from gene-modified tumor cells may help the body build an effective immune response to kill pancreatic cancer cells.
- Trial name
- NCT00727441
- Testing
- GVAX pancreatic cancer vaccine, cyclophosphamide
- Where
- United States
- Volunteers
- 87 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Pancreatic Neoplasms, Cancer of the Pancreas
Gemcitabine and CT-011 for Resected Pancreatic Cancer
Background: In 2009, 49,096 patients were diagnosed with pancreatic cancer. Pancreatic cancer carries a poor prognosis with an overall 5-year relative survival rate of 5.6%.
- Conditions
- Pancreatic Neoplasms, Cancer of the Pancreas, Neoplasms Pancreatic, Pancreatic Cancer
- Trial name
- NCT01313416
- Testing
- CT-011, Gemcitabine
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Augusta University
Pancreatic Cancer
Safety, Tolerability, and Efficacy of mFOLFIRINOX ± BNT321 as Adjuvant Therapy Following Curative Resection in Patients With Pancreatic Adenocarcinoma
This study was designed as a Phase 1/randomized Phase 2 open-label study of modified(m) FOLFIRINOX ± BNT321 for adjuvant therapy in pancreatic ductal adenocarcinoma (PDAC) patients post R0 or R1 resection.
- Trial name
- NCT06069778
- Testing
- BNT321 0.5 mg/kg, BNT321 DL 2, mFOLFIRINOX
- Where
- 2 sites in United States
- Volunteers
- 1 people
- Sponsor
- BioNTech SE
Pancreatic Cancer
Trial to Improve Outcomes in Patients With Resected Pancreatic Cancer (Azacitidine)
To improve progression free survival in high risk patients with resected pancreatic adenocarcinoma who have node positive disease, margin positive disease, and/or elevation in CA 19-9 treated with CC-486 (oral azacitidine) as…
- Trial name
- NCT01845805
- Testing
- oral azacitidine, Observation
- Where
- 4 sites in United States
- Volunteers
- 49 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Pancreatic Cancer
BrUOG 295: Adjuvant FOLFOX-A For Resected Pancreatic Cancer: A Phase II Brown University Oncology Research Group Trial
The investigators preliminary data suggests that FOLFOX-A may have equal or superior activity as compared to FOLFIRINOX and appears to be better tolerated.
- Trial name
- NCT02022033
- Testing
- FOLFOXA
- Where
- 2 sites in United States
- Volunteers
- 25 people
- Sponsor
- Brown University